Cross-sectional comparative and analytical study of PD patients from a multicentric mexican PD cohort (n=306) evaluated in 2017-2018. Demographic and clinical variables were documented as predictive and depressive symptoms (MDS-UPDRS item 1.3) as outcome variables. Those with significant association were used to construct multivariate regression model to identify predictive factors.

57.8% (177/306) reported depressive symptoms. Right-sided symptom onset (P = .020), PIGD subtype (P = .001), Hoehn & Yahr III-IV (P = .006), MDS-UPDRS part III (P = .002), presence of cognitive impairment (P = .007), psychosis (P = .030), anxiety (P = <.001), apathy (P= <.001), sleep problems (P = .020), pain (P = .007), drooling (P = .033), gait problems (P = .002), and freezing of gait (P = .001) were significantly associated with depression.

Multivariate analysis proved the presence of anxiety (OR = 5.23, P = <.001), freezing of gait (OR = 3.44, P = .002), and apathy (OR = 2.52, P = 0.030) to be significant predictors for depression. MAOBIs were found to be a protective factor for depression (OR = 0.46, P = 0.039). [table1] When comparing MAOBIs, selegiline was associated with lower presence of depression compared to rasagiline (OR = 0.19, P = 0.022). The model showed an accuracy of 71.9%, sensitivity 79.4%, specificity 64.2%, PPV 69.5%, and NPV 75.2%.

Prevalence and associated factors with depression are congruent with previously reported data. Treating apathy, freezing of gait, and anxiety might improve depression. Better designed studies are needed to confirm the antidepressive role of MAOBIs.